Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > ARCHIVE
ARCHIVE
- Abstract of PII for CBP501 Presented at IMIG2010: CanBas
September 27, 2010
- Prof. Morishita Calls For Creation of Environment Friendly to Bioventures
September 27, 2010
- 30% Market Share for Generics Unlikely to Be Achieved: Mr Mitsuhara
September 27, 2010
- Rozerem Ranked No. 1 in Both HP, GP Markets: RepTrack Survey
September 27, 2010
- Korosho Confirms “Principle of Nondiscrimination”for Generics Applied by Indian Firms
September 27, 2010
- Ritsuo Hosokawa Appointed New Health Minister
September 27, 2010
- Taiyo, Kyowa Should Be More Severely Punished: Nichibyokyo
September 27, 2010
- Bendamustine Launched in Singapore: SymBio, Eisai
September 27, 2010
- The Pharma Gospel of Praise
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
September 27, 2010
- Daiichi Sankyo Wins Appellate Court Litigation against Mylan
September 27, 2010
- Torisel Ensures Good Compliance with IV Infusion Once a Week: Prof. Horie
September 27, 2010
- Re-Pricing Rule to Be Included in Chuikyo Agenda: Mr Yoshida
September 27, 2010
- Actemra to Change Paradigm for Treatment of RA: Chugai
September 27, 2010
- Int'l Harmonization Conference to Be Created on Drug-Device Combination Products
September 27, 2010
- All-Patients Post-Marketing Investigation on Avastin Finished
September 27, 2010
- Korosho to Support Development of First-in-Class Drugs
September 27, 2010
- Use of Robot in Prostatectomy to Be Approved as Senshin-iryo
September 27, 2010
- Toyobo to Strengthen Bulk Manufacturing & Contract R&D for Biopharmaceuticals
September 27, 2010
- 29 Ex-Korosho Officials Employed by 15 Drug Firms
September 27, 2010
- Mochida Applies for Escitalopram in Japan
September 27, 2010
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…